Oncology and Carcinogenesis articles for The University of Texas MD Anderson Cancer Center, United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 228

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
1 0.06
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention 0.06
2 0.92
Development and Validation of a Histology-Specific Natural History Model of Ovarian Cancer 0.79
Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II study 0.13
2 0.07
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.02
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer. 0.04
11 2.69
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.01
Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia 1.00
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.03
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia 0.37
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.05
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.02
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin 0.10
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of iJAK2/i-mutated post-MPN AML 0.26
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma 0.08
Restoring p53-wild type conformation in TP53-Y220C mutant acute myeloid leukemia 0.73
1 0.02
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.02
11 2.74
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer 0.17
Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia 0.01
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence 0.02
Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression 0.00
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors 0.60
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest 0.58
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF metastatic colorectal cancer 0.71
CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases 0.00
Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy 0.00
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer 0.65
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma 0.00
8 2.68
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer 0.05
Comprehensive Multi-Omic Characterization of Perineural Invasion in Cervical Cancer Reveals Diagnostic Markers, Molecular Drivers, and Therapeutic Strategies 0.09
Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis 0.03
KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer 0.81
In Silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response 0.40
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy. 0.02
The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer 0.28
Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy 1.00
5 0.29
Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis 0.00
Disrupted molecular glue complex drives RAS inhibitor resistance 0.04
Unbiased niche labeling maps immune-excluded niche in bone metastasis 0.07
Vagal blockade of the brain-liver axis deters cancer-associated cachexia 0.18
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis 0.00
2 0.10
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia 0.03
TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice 0.07
1 0.25
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU. 0.25
1 0.10
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer 0.10
3 2.00
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer 0.89
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder 0.29
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial 0.82
2 0.12
An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study 0.03
Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study 0.09
1 0.02
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.02
1 0.06
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.06
4 0.30
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment 0.00
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.25
IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy 0.00
IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy 0.04
3 1.19
Immunotherapy Response in Microsatellite Instability–High Gastroesophageal Adenocarcinoma 1.00
An American College of Surgeons National Quality Improvement Collaborative to Enhance Lung Cancer Surgical Quality 0.07
Esophagectomy vs Active Surveillance in Clinical Complete Responders After Neoadjuvant Chemoradiation 0.13
1 0.08
A Direct-to-Patient Digital Health Program for Lung Cancer Screening 0.08
3 0.21
KRASG12D mutation promotes pancreatic tumorigenesis by suppressing sirtuin three via the guanine nucleotide exchange factor RCC1 0.13
Rules of engagement: Determinants of chemokine receptor activation and selectivity by CCL27 and CCL28 0.06
Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism 0.02
2 1.38
Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules 0.38
Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues 1.00
5 0.79
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model 0.04
NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress 0.08
Osimertinib activates a TGFβ2-dependent secretory program that drives lung adenocarcinoma progression 0.59
USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer 0.03
Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma 0.05
25 4.28
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial 0.90
Concurrent versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of “High Risk” Early Breast Cancer: NRG/RTOG 1005 Phase III Trial 0.04
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. 0.04
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.02
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. 0.05
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. 0.03
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. 0.04
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. 0.15
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. 0.08
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. 0.08
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. 0.25
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma. 0.10
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. 0.02
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. 0.07
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. 0.05
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report. 0.39
Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. 0.77
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.06
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.02
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay. 0.04
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. 0.03
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. 0.05
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). 0.02
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. 0.03
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. 0.97
1 0.06
Tumor cell heterogeneity drives spatial organization of the intratumoral immune response 0.06
3 1.11
Global patterns of mutational profiles in biliary tract cancer 1.00
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma 0.08
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma 0.03
1 0.05
Cofilin inhibition ameliorates PIEZO2 and AMPA dysfunction in a mouse model of Angelman syndrome 0.05
2 0.76
Early compliance with lung cancer lymph node standard 5.8: An analysis of 2022 and 2023 Commission on Cancer site reviews 0.05
Extent of resection in surgically resected stage IV non−small cell lung cancer: Results from two tertiary referral centers 0.71
1 0.90
Long-term outcomes in juvenile-onset mycosis fungoides 0.90
1 0.17
Long-Lived Immunogenic Cell Death Induced by a Water-Soluble Redox Active Au(I) Bis-N-Heterocyclic Carbene 0.17
8 1.16
Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium 0.23
<atl>Impact of iKRAS/i codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab</atl> 0.61
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience 0.09
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.01
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.01
Mortality after colorectal cancer among survivors of childhood cancer 0.06
The association between clinical trial participation, drug costs, and performance in the Oncology Care Model 0.14
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer 0.01
3 1.11
HSP90 buffers deleterious genetic variations in BRCA1 0.93
Accumulation of succinate suppresses de novo purine synthesis through succinylation-mediated control of the mitochondrial folate cycle 0.07
β-catenin functions as a molecular adapter for disordered cBAF interactions 0.11
8 3.18
Ecotypes of triple-negative breast cancer in response to chemotherapy 0.92
Evolutionary characterization of lung cancer metastasis 0.01
A glucocorticoid–FAS axis controls immune evasion during metastatic seeding 0.00
The ubiquitin ligase KLHL6 drives resistance to CD8 T cell dysfunction 0.01
Somatic evolution following cancer treatment in normal tissue 0.00
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade 0.81
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy 0.65
PPP2R1A mutations portend improved survival after cancer immunotherapy 0.78
2 0.70
Cancer-associated fibroblasts regulate DNA repair in pancreatic cancer through NDRG1-mediated R-loop processing 0.03
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer 0.67
31 6.21
Potential for risk reduction of chronic health conditions through lifestyle in childhood cancer survivors 0.06
High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities 0.04
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy 0.00
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial 0.17
A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy 0.08
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial 0.04
Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures 0.79
Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction 0.18
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study 0.11
The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study 0.00
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer 0.07
A hormetic transcriptional program coregulates invasion, proliferation and dormancy to define metastatic potential 0.04
Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4 0.08
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial 0.01
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction 0.88
Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer 1.00
ER degradation for ER+/HER2– advanced or metastatic breast cancer: a phase 1 trial 0.11
Early genetic evolution of driver mutations in uveal melanoma 0.03
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors 0.04
Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral blood 0.06
Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer 0.61
The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells 0.04
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer 0.00
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence 0.96
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer 0.13
In vivo CRISPR screening in head and neck cancer reveals as an immunotherapy target 0.02
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity 0.50
Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC 0.08
Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma 0.02
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B 0.06
Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny 0.00
4 0.87
Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry 0.05
Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer 0.02
The long-term effects of chemotherapy on normal blood cells 0.03
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation 0.77
14 1.90
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial 0.03
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial 0.04
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial 0.00
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial 0.45
Abemaciclib in meningiomas with somatic or CDK pathway alterations: the phase 2 Alliance A071401 trial 0.03
CD4 T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy 0.00
Microbial signals in primary and metastatic brain tumors 0.83
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial 0.11
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.04
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses 0.07
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results 0.07
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.15
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial 0.04
1 1.00
The deubiquitinating enzyme Cezanne stabilizes BRCA1 by counteracting APC/C and Ube2S-dependent Lys11-linked ubiquitination 1.00
1 0.21
Spatial colocalization and molecular crosstalk of myofibroblastic CAFs and tumor cells shape lymph node metastasis in oral squamous cell carcinoma 0.21
10 4.55
Deep-learning endomicroscope with large field-of-view and depth-of-field for real-time in vivo imaging of epithelial cancer hallmarks 0.25
Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion 0.90
Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade 0.00
Viral mimicry may help explain immunogenic cell death 0.33
Elucidating cooperative genetic events in DCIS progression in mutant p53–driven breast cancer 0.90
Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy 0.04
Deciphering precursor cell dynamics in esophageal preneoplasia via genetic barcoding and single-cell transcriptomics 1.00
Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell–engineered mesothelin-redirected CAR-NKT cells 0.00
Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle 0.13
Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas 1.00
2 1.09
Feasibility of Auditing Preoperative Breast MRI for Extent-of-Disease Evaluation Using the BI-RADS v2025 Manual. 1.00
Molecular Breast Imaging and Digital Breast Tomosynthesis for Dense Breast Screening: The Density MATTERS Trial. 0.09
3 0.14
Intermetallic nanoassemblies potentiate systemic STING activation 0.07
The synaptic ectokinase VLK triggers the EphB2–NMDAR interaction to drive injury-induced pain 0.06
In vivo CAR T cell generation to treat cancer and autoimmune disease 0.00
8 1.84
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC 0.81
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis 0.06
<atl>Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and iBAP1/i loss</atl> 0.00
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer 0.00
Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases 0.00
Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy 0.88
Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTs 0.06
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation 0.02
5 1.84
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors 0.00
Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia 0.18
Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts 0.89
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses 0.19
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer 0.58
4 0.66
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial 0.04
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis 0.02
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.03
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial 0.57
10 1.53
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial 0.06
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration 0.28
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.02
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.04
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial 0.06
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.03
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 0.06
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 0.07
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial 0.87
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study 0.06
10 0.43
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations 0.03
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.03
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer 0.05
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.04
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors 0.06
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer 0.03
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.05
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.03
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 0.07

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.